Mitsubishi Chemical Group Corporation
4188・Prime Market・Chemicals
Business
Mitsubishi Chemical Group is a comprehensive chemical group composed of the Company, 350 consolidated subsidiaries, and 139 affiliated companies and others. It comprises four segments: Specialty Materials (high-functionality films, engineering plastics, carbon fiber, etc.), MMA & Derivatives (MMA Monomer/PMMA, Coatings & Additives), Basic Materials & Polymers (petrochemical base products, polyolefins, carbon), and Industrial Gases (global industrial gases centered on Nippon Sanso Holdings). Its main customers span diverse industries such as semiconductors, mobility, food packaging materials, and healthcare, and it maintains a global production and sales network spanning Japan, North America, Europe, and Asia Pacific. In July 2025, the company completed the transfer of all shares of Mitsubishi Tanabe Pharma, completing a structural transformation to concentrate management resources on Chemicals and Industrial Gases.
Business Model
The Industrial Gases segment has a stable earnings model based on long-term supply contracts and on-site supply, and serves as the earnings pillar accounting for approximately 89% of the Group's core operating income. Specialty Materials secures profit by maintaining and improving the selling prices of high-value-added products for growth markets such as semiconductors and mobility. Basic Materials & Polymers/MMA is market-linked, but the company aims to improve earnings through structural reforms and cost reductions. Capital expenditure and R&D expenses are allocated with a focus on growth segments, and the company pursues improved capital efficiency with ROIC improvement as a management indicator.
Company Strengths
The Industrial Gases segment recorded revenue of ¥1,352,498 million and core operating income of ¥200,706 million (core operating margin of approximately 14.8%) in FY2026 (ending March 2026), accounting for approximately 89% of the group's overall core operating income of ¥225,000 million. In addition to a stable earnings structure underpinned by long-term supply contracts and on-site supply, the segment has driven ¥62.2 billion (company-wide) in cost reductions through DX utilization and plant operation optimization, forming an earnings base that is less susceptible to market fluctuations.
The Specialty Materials segment holds a portfolio of high-value-added products, including high-performance engineering plastics for semiconductor manufacturing equipment, carbon fiber composite parts for robotaxis, and EUV dry resist materials (Gelest, Inc.). In FY2026 (ending March 2026), core operating income for this segment was ¥32.3 billion, an increase of ¥8.4 billion year on year, achieving both maintenance/improvement of selling prices and increased sales volume simultaneously. Capital expenditure also reached ¥131,574 million, the largest scale among all segments, as the company continues to strengthen its technology and production base.
In the Industrial Gases segment, the company executed the acquisition of Coregas Group in Australia and New Zealand, as well as the acquisition of a home healthcare services business (ETH) in Spain, Europe, steadily advancing geographic expansion and diversification of its customer base. The consolidation effects of these acquisitions were a major factor increasing Industrial Gases revenue by ¥51.4 billion year on year in FY2026 (ending March 2026), demonstrating the company's execution capability in expanding business scale through M&A.
ENVALITH's Perspective
Performance Trend
Revenue for FY2026 (ending March 2026) was ¥3,703,988 million (down 6.2% year on year). The main drivers were the classification of the Pharma business as a discontinued operation, along with a decline in MMA Monomer market prices and lower sales volume in Basic Materials. Core operating profit remained resilient at ¥225,002 million (down 1.7% year on year), but non-recurring losses—including a provision for restructuring of ¥59,249 million, special retirement payments of ¥53,091 million, and impairment losses of ¥61,405 million—caused operating profit to plunge to ¥30,078 million (down 78.8% year on year), with profit before tax collapsing to ¥711 million (down 99.3% year on year). Profit attributable to owners of the parent was ¥11,829 million (down 73.7% year on year). Profit of ¥94,780 million from discontinued operations (including a ¥128,600 million gain on the transfer of Mitsubishi Tanabe Pharma) supported net profit for the period. Operating profit over the past five fiscal years has followed a declining trend: ¥303,194 million in FY2022, ¥182,718 million in FY2023, ¥261,831 million in FY2024, ¥196,694 million in FY2025, and ¥30,078 million in FY2026, underscoring the urgent need for structural reform costs to run their course.
Growth Strategy
Aim to achieve the 2029 targets through concentration on specialty chemicals and industrial gases and portfolio restructuring
Acquired Coregas Group in Australia (acquisition price ¥71,521 million, completed July 2025) and ETH in Spain (¥22,432 million, completed March 2026), strengthening the business foundation in Oceania and Europe. Through price management initiatives and cost reductions in each region, core operating profit in the Industrial Gases segment for FY2026 (ending March 2026) increased by ¥14.6 billion year on year to ¥200,706 million. Further profit growth is expected in FY2027 (ending March 2027).
Completed the transfer of all shares and related assets of Mitsubishi Tanabe Pharma to a Bain Capital-affiliated fund effective July 1, 2025. Secured cash consideration of ¥536,800 million, which was applied to interest-bearing debt reduction (interest-bearing debt including leases reduced by ¥156.6 billion year on year) and funding for the industrial gases acquisitions. The net D/E ratio improved to 0.83, strengthening the financial base.
Decided to withdraw from the coke and carbon materials business, recording a restructuring provision of ¥54,085 million and impairment losses of ¥16,300 million, among other charges. Also decided to implement the Next Stage support program (special retirement payments of ¥31,885 million) at Mitsubishi Chemical Corporation. Aiming to improve the earnings structure of the Basic Materials & Polymers segment.
Promoting increased sales of high-performance engineering plastics and carbon fiber composite parts for semiconductor manufacturing equipment, along with rationalization through review of production sites across businesses. Segment core operating profit for FY2026 (ending March 2026) improved by ¥8.4 billion year on year to ¥32,309 million. Further profit growth is expected in FY2027 (ending March 2027) through increased sales of each product and cost reductions.
The MMA & Derivatives segment recorded a core operating loss of ¥1,538 million in FY2026 (ending March 2026). A bottoming-out and rebound of the MMA monomer market is positioned as a key profit driver for FY2027 (ending March 2027), and together with a recovery in demand for Coatings & Additives, the segment aims to return to profitability. The timing and magnitude of the market recovery remain uncertain as external factors.
Last updated: July 19, 2026